<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02472314</url>
  </required_header>
  <id_info>
    <org_study_id>2014-193</org_study_id>
    <nct_id>NCT02472314</nct_id>
  </id_info>
  <brief_title>Exparel for Postoperative Pain Management in Shoulder Surgery</brief_title>
  <official_title>A Novel Application of Exparel for Postoperative Pain Management in Shoulder Arthroplasty and Humerus Fracture Fixation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wayne State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of liposomal Bupivacaine infiltration into
      the shoulder to continues nerve block with Bupivacaine on postoperative pain control and
      functional outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      liposomal bupivacaine analgesia will provide improved postoperative pain control, reduction
      in amount of opioid supplementation, decreased complications and faster return to function
      compared to current standard of care pain management for patients undergoing shoulder
      arthroplasty and shoulder surgery for proximal humerus fractures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Analgesia</measure>
    <time_frame>30 days</time_frame>
    <description>Quality of analgesia as measured by numerical rating scores for pain (active and at rest) as (0=no pain, 10= worst pain) every two hours for the initial 36 hours, then on day2, day7 and day30 postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post Operative American Shoulder and Elbow Surgeons (ASES)</measure>
    <time_frame>Preoperative, 6 weeks and last follow up</time_frame>
    <description>American Shoulder and Elbow Surgeons (ASES) score is an outcome reporting measure for assessments of shoulder function in patients with shoulder pathology and after shoulder arthroplasty surgery. ASES is a 100 points scale consisting of two measures: one pain scale (worth 50 points) and 10 activities of daily living(worth 50 points), the total score is the sum of both and the higher total score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Shoulder Value (SSV)</measure>
    <time_frame>Pre-operative, 6 weeks and last Follow up</time_frame>
    <description>Functional assessments after shoulder arthroplasty surgery. The SSV is defined as a patient's subjective shoulder assessment expressed as a percentage of an entirely normal shoulder, which would score 100%. The range is between 0% and 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Nerve Injury</measure>
    <time_frame>During hospital stay and at 2 weeks and 6 weeks post-operatively</time_frame>
    <description>Neuropraxia on the treatment side</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Fracture of Shoulder and Upper Arm</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CISB control for A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One time injection of 1.3% Liposomal Bupivacaine during Humerus Fracture Fixation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CISB control for B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peripheral nerve block (CISB) with 0.125% bupivacaine during fracture fixation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.3% Liposomal Bupivacaine</intervention_name>
    <description>local tissue infiltration of Liposomal Bupivacaine during surgery</description>
    <arm_group_label>Liposomal Bupivacaine A</arm_group_label>
    <arm_group_label>Liposomal Bupivacaine B</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.125% Bupivacaine</intervention_name>
    <description>Continues nerve block with Bupivacaine during surgery and postoperatively</description>
    <arm_group_label>CISB control for A</arm_group_label>
    <arm_group_label>CISB control for B</arm_group_label>
    <other_name>Bupivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing shoulder arthroplasty under general anesthesia

          -  Patients undergoing open reduction internal fixation (ORIF) of a proximal humerus
             fracture under general anesthesia

          -  Patients with American Society of Anesthesiologist (ASA) physical status
             classification of 1-3

          -  Patients meeting criteria for standard of care continuous peripheral nerve block
             (CPNB) per anesthesia guidelines.

          -  Patients agreeing to be available for brief follow up telephone survey post-
             operatively and being mentally able to respond.

          -  Patients available for follow up routine post-operative clinic visits, per standard of
             care.

        Exclusion Criteria:

          -  Contraindications to regional anesthesia

          -  Significant peripheral neuropathy or neurological disorder affecting the upper
             extremity

          -  Contraindication to a component of multimodal analgesia

          -  Pregnancy

          -  Opioid tolerance

          -  Cognitive or psychiatric condition that might affect patient assessment and/or
             inability to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wayne State University Physician Group</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2015</study_first_posted>
  <results_first_submitted>November 28, 2018</results_first_submitted>
  <results_first_submitted_qc>March 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 16, 2019</results_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wayne State University</investigator_affiliation>
    <investigator_full_name>Vani J. Sabesan</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Shoulder Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 14, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT02472314/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This prospective, randomized, controlled study included 70 consecutive shoulder arthroplasty patients from August 2015 through June 2016 during the period of 1 year at one location.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Liposomal Bupivacaine A</title>
          <description>One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty
1.3% Liposomal Bupivacaine: local tissue infiltration of Liposomal Bupivacaine during surgery</description>
        </group>
        <group group_id="P2">
          <title>CISB Control for A</title>
          <description>Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .
0.125% Bupivacaine: Continues nerve block with Bupivacaine during surgery and postoperatively</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liposomal Bupivacaine A</title>
          <description>One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty
1.3% Liposomal Bupivacaine: local tissue infiltration of Liposomal Bupivacaine during surgery</description>
        </group>
        <group group_id="B2">
          <title>CISB Control for A</title>
          <description>Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .
0.125% Bupivacaine: Continues nerve block with Bupivacaine during surgery and postoperatively</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical Side</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Left</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Arthroplasty type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hemi</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reverse</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quality of Analgesia</title>
        <description>Quality of analgesia as measured by numerical rating scores for pain (active and at rest) as (0=no pain, 10= worst pain) every two hours for the initial 36 hours, then on day2, day7 and day30 postoperatively</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine A</title>
            <description>One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty
1.3% Liposomal Bupivacaine: local tissue infiltration of Liposomal Bupivacaine during surgery</description>
          </group>
          <group group_id="O2">
            <title>CISB Control for A</title>
            <description>Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .
0.125% Bupivacaine: Continues nerve block with Bupivacaine during surgery and postoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Analgesia</title>
          <description>Quality of analgesia as measured by numerical rating scores for pain (active and at rest) as (0=no pain, 10= worst pain) every two hours for the initial 36 hours, then on day2, day7 and day30 postoperatively</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 24 to 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="2.6" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="4.0" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="2.6" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="2.2" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Operative American Shoulder and Elbow Surgeons (ASES)</title>
        <description>American Shoulder and Elbow Surgeons (ASES) score is an outcome reporting measure for assessments of shoulder function in patients with shoulder pathology and after shoulder arthroplasty surgery. ASES is a 100 points scale consisting of two measures: one pain scale (worth 50 points) and 10 activities of daily living(worth 50 points), the total score is the sum of both and the higher total score indicates better outcome.</description>
        <time_frame>Preoperative, 6 weeks and last follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine A</title>
            <description>One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty
1.3% Liposomal Bupivacaine: local tissue infiltration of Liposomal Bupivacaine during surgery</description>
          </group>
          <group group_id="O2">
            <title>CISB Control for A</title>
            <description>Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .
0.125% Bupivacaine: Continues nerve block with Bupivacaine during surgery and postoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>Post Operative American Shoulder and Elbow Surgeons (ASES)</title>
          <description>American Shoulder and Elbow Surgeons (ASES) score is an outcome reporting measure for assessments of shoulder function in patients with shoulder pathology and after shoulder arthroplasty surgery. ASES is a 100 points scale consisting of two measures: one pain scale (worth 50 points) and 10 activities of daily living(worth 50 points), the total score is the sum of both and the higher total score indicates better outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-operative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="20.04"/>
                    <measurement group_id="O2" value="27.7" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Weeks after surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5" spread="18.1"/>
                    <measurement group_id="O2" value="57.3" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Followup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" spread="22.7"/>
                    <measurement group_id="O2" value="59.7" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Shoulder Value (SSV)</title>
        <description>Functional assessments after shoulder arthroplasty surgery. The SSV is defined as a patient's subjective shoulder assessment expressed as a percentage of an entirely normal shoulder, which would score 100%. The range is between 0% and 100%</description>
        <time_frame>Pre-operative, 6 weeks and last Follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine A</title>
            <description>One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty
1.3% Liposomal Bupivacaine: local tissue infiltration of Liposomal Bupivacaine during surgery</description>
          </group>
          <group group_id="O2">
            <title>CISB Control for A</title>
            <description>Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .
0.125% Bupivacaine: Continues nerve block with Bupivacaine during surgery and postoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Shoulder Value (SSV)</title>
          <description>Functional assessments after shoulder arthroplasty surgery. The SSV is defined as a patient's subjective shoulder assessment expressed as a percentage of an entirely normal shoulder, which would score 100%. The range is between 0% and 100%</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="24.3" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 6 weeks post-op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.7" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="63.1" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At last follow up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="69.3" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Nerve Injury</title>
        <description>Neuropraxia on the treatment side</description>
        <time_frame>During hospital stay and at 2 weeks and 6 weeks post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine A</title>
            <description>One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty
1.3% Liposomal Bupivacaine: local tissue infiltration of Liposomal Bupivacaine during surgery</description>
          </group>
          <group group_id="O2">
            <title>CISB Control for A</title>
            <description>Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .
0.125% Bupivacaine: Continues nerve block with Bupivacaine during surgery and postoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Nerve Injury</title>
          <description>Neuropraxia on the treatment side</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Three months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Liposomal Bupivacaine A</title>
          <description>One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty
1.3% Liposomal Bupivacaine: local tissue infiltration of Liposomal Bupivacaine during surgery</description>
        </group>
        <group group_id="E2">
          <title>CISB Control for A</title>
          <description>Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .
0.125% Bupivacaine: Continues nerve block with Bupivacaine during surgery and postoperatively</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD</sub_title>
                <description>Respiratory insufficiency in a chronic obstructive pulmonary disease and sleep apnea</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>catheter malposition</sub_title>
                <description>Residual numbness of the hand and neck</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Catheter fall out</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The NRS pain scale has been associated with higher patient-reported pain scores
Surgeons were not blinded to intervention as they had to perform the injection
Surgeons were involved with the assessment portion of the outcome evaluations</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Vani J. Sabesan, MD</name_or_title>
      <organization>Wayne State University School of Medicine and Cleveland Clinic Florida</organization>
      <phone>131375138489</phone>
      <email>sabes001@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

